Depressive Disorder Clinical Trial
Official title:
Development of Outpatient MST for Dually Diagnosed Youth
Adolescent substance abuse results in significant negative outcomes and extraordinary costs for youths, their families, communities, and society. Moreover, rates of psychiatric comorbidity among substance abusing youth range from 25% up to 82%, and youths with a dual diagnosis have worse outcomes and are more than twice as costly to treat than their counterparts with no comorbidity. This project was a pilot test of a new treatment, OPTION-A, which was adapted from Multisystemic Therapist (MST) and other evidence-based interventions to specifically treat youth presenting for outpatient treatment of comorbid substance use and internalizing disorders. The project was a randomized controlled pilot trial comparing the experimental treatment to usual services in the community.
Adolescent substance abuse results in significant negative outcomes and extraordinary costs
for youths, their families, communities, and society. Moreover, rates of psychiatric
comorbidity among substance abusing youth are high and youths with a dual diagnosis are more
costly to treat. At the time of this study, however, no outpatient treatments had been tested
specifically for treating youth with co-occurring substance use disorders and mental health
diagnoses. The current project aimed to adapt and evaluate Multisystemic Therapy (MST), a
well validated treatment for chronic behavioral problems or serious emotional disturbance in
adolescents, to treat dually diagnosed youth using an outpatient model of service delivery.
A pilot trial was conducted with 40 dually diagnosed youth randomly assigned to treatment
conditions, with 20 receiving the experimental treatment (OPTION-A) and 20 receiving usual
outpatient services. Specific aims were:
Specific Aim 1: The primary aim of the present research was to adapt and test OPTION-A for
use in outpatient settings to treat youth diagnosed with a substance use disorder and
comorbid internalizing disorder. We hypothesized that youth receiving OPTION-A would exhibit
significantly less drug use (e.g., youth self-reports and urine screens) than control youth
who received usual services, and that youth receiving OPTION-A would exhibit significant
improvement on indices of mental health (e.g., combined youth and caregiver reports on
diagnostic interviews and youth, caregiver, and teacher reports of internalizing symptoms)
compared to control youth Specific Aim 2: In addition to improved symptomatology, the current
research aimed to test the effectiveness of OPTION-A to improve youth functioning in other
domains pertinent to successful adolescent development. We hypothesized that youth receiving
OPTION-A would evidence improved behavioral (e.g., youth, caregiver, and teacher reports of
externalizing), school (e.g., school attendance), and family functioning (e.g., youth and
caregiver reports of family adaptability and cohesion) compared to control youth who received
usual services.
Specific Aim 3: The final aim of the proposed research was to provide services that are more
acceptable to consumers than are usual services provided in the community. We hypothesized
that youth and families receiving OPTION-A would experience significantly greater consumer
satisfaction than control youth and families who received usual services.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01316926 -
Paxil CR Bioequivalence Study Brazil
|
Phase 1 | |
Recruiting |
NCT06187454 -
Transcranial Direct Current Stimulation for Depression
|
N/A | |
Completed |
NCT04469322 -
Pharmacogenetic Implementation Trial in Veterans With Treatment Refractory Depression
|
N/A | |
Recruiting |
NCT05768126 -
Prediction of ECT Treatment Response and Reduction of Cognitive Side-effects Using EEG and Rivastigmine
|
Phase 4 | |
Completed |
NCT03219879 -
Telephone-administered Relapse Prevention for Depression
|
N/A | |
Recruiting |
NCT06038721 -
Unified Protocol: Community Connections
|
N/A | |
Completed |
NCT03043560 -
Study to Treat Major Depressive Disorder With a New Medication
|
Phase 2 | |
Completed |
NCT04091139 -
Research of Unified Protocol for the Treatment of Common Mental Disorders in Adolescents in Hong Kong
|
Phase 2/Phase 3 | |
Completed |
NCT00069459 -
Seasonal Affective Depression (SAD) Study
|
Phase 1 | |
Recruiting |
NCT05503966 -
Combining Antidepressants and Attention Bias Modification in Depression
|
N/A | |
Recruiting |
NCT03001245 -
Interpersonal Counseling (IPC) for Treatment of Depression in Adolescents
|
N/A | |
Completed |
NCT02939560 -
TMS for Adults With Autism and Depression
|
N/A | |
Completed |
NCT02542891 -
European Comparative Effectiveness Research on Internet-based Depression Treatment
|
N/A | |
Completed |
NCT02452892 -
Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
|
N/A | |
Completed |
NCT02224508 -
Evaluation of a Health Plan Initiative to Mitigate Chronic Opioid Therapy Risks
|
N/A | |
Completed |
NCT02306551 -
Well Being And Resilience: Mechanisms of Transmission of Health and Risk
|
||
Withdrawn |
NCT02238730 -
Ultrabrief Right Unilateral and Brief Pulse Bitemporal Electroconvulsive Therapy
|
N/A | |
Completed |
NCT01407575 -
Buprenorphine for Treatment Resistant Depression
|
Phase 3 | |
Completed |
NCT01597661 -
Bupropion & Cardio Birth Defect (Slone)
|
N/A | |
Completed |
NCT01093053 -
Mind-Body Skills Groups for the Treatment of War Zone Stress in Military and Veteran Populations
|
N/A |